Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Endorphins make you happy. But research suggests that this mental health boost may occur even when people dont lose weight
Future GLP-1 trends: new drugs and therapies on the horizon The future of weight management may soon involve more than current GLP-1s: Amylin mimetics: These compounds mimic another satiety hormone and may complement GLP-1s. Mazdutide: A dual glucagon/GLP-1 agonist showing strong Phase 3 results and promising greater weight loss. Oral GLP-1s: Pills in development could improve convenience. Muscle-preserving combinations: Researchers are exploring co-therapies to prevent loss of lean mass during weight loss. Providers should prepare for a rapidly evolving landscape and educate patients about upcoming options. Key takeaways on GLP-1 trends for providers and patients Efficacy varies across drugs and doses
On the heels of basic research on the venom of Gila monsters in the preceding decades,1 exenatide secured the first US FDA approval in the class on April 28, 2005.2 While the prominent GLP-1 brand names are household names today, the class was off to a relatively slow start at first five years passed before it reached blockbuster status (US$1 billion (770 million) in sales), and another five went by before the first formal approval of a GLP-1 drug indicated for obesity became a reality.3 Last year saw sales for the class cross $50 billion and, with another 40% in revenue growth in store for 2025, the GLP-1 segment of the pharmaceutical industry is firmly in the rapid growth phase of the market, per Investment Bank Consensus
HUADONG MEDICINE, via its subsidiary Hangzhou Zhongmei HuaDong Pharmaceutical CO
US$ 24.80
US$ 29.46
US$ 28.78
